UK markets open in 4 hours 13 minutes

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.0700+0.0700 (+2.33%)
At close: 04:00PM EST
3.0700 0.00 (0.00%)
After hours: 04:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.0000
Open3.1100
Bid3.0200 x 1000
Ask3.0700 x 900
Day's range3.0100 - 3.1100
52-week range2.3300 - 7.3800
Volume40,591
Avg. volume272,514
Market cap337.147M
Beta (5Y monthly)2.20
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    DBV Technologies to Participate in an Upcoming Investor Conference

    Montrouge, France, November 24, 2021 DBV Technologies to Participate in an Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 4th Annual Evercore ISI HealthCONx Conference. Daniel Tassé, Chief Executive Officer, will participate in a fireside chat on Wednesday, December 1st at 8am ET. A live webcast of the fireside chat will be available on the Investo

  • Globe Newswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights10/31/202155,011,687 Total gross of voting rights: 55,011,687 Total net* of voting rights: 54,910,187 * Total net = total number of voting rights attached to shares – shares wit

  • Globe Newswire

    DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021

    Montrouge, France, November 1, 2021 DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new clinical study results on the use of Viaskin™ Peanut (DBV712) 250 μg in children will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, Nov. 4-8, 2021. Two abstracts have been